Nancy L Bartlett

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Scott E Smith, Bruce D Cheson, Andreas Engert, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Bruce D Cheson, R. Advani, J. Winter, 2014, Journal of Hematology & Oncology.

Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma.

Angelique Zeringue, Kenneth R Carson, Jingxia Liu, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

John P Leonard, J. Leonard, A. Younes, 2010, The New England journal of medicine.

Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma

Roland Schmitz, Bao Tran, Yongmei Zhao, 2018, The New England journal of medicine.

A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma

Ying Luan, J. Vose, L. Gordon, 2015, Clinical Cancer Research.